Top-News

RXI PHARMACEUTICALS News

Keine aktuellen Kursdaten verfügbar
ISIN: US74979C1053
Typ: Aktie

RXI PHARMACEUTICALS News

25.03.21 - PR Newswire
Phio Pharmaceuticals Reports 2020 Year End Financial Results and Provides Business Update
Phio Pharmaceuticals Reports 2020 Year End Financial Results and Provides Business Update PR Newswire
11.03.21 - PR Newswire
Phio Pharmaceuticals To Present New Data on PD-1 Targeting INTASYL at the 2021 American Association for Cancer Research (AACR) Annual Meeting
Phio Pharmaceuticals To Present New Data on PD-1 Targeting INTASYL at the 2021 American Association for Cancer Research (AACR) Annual Meeting PR Newswire
01.03.21 - PR Newswire
Phio Pharmaceuticals and AgonOx, Inc. Announce Collaboration on Clinical Development of Novel T Cell-based Cancer Immunotherapies
Phio Pharmaceuticals and AgonOx, Inc. Announce Collaboration on Clinical Development of Novel T Cell-​based Cancer Immunotherapies PR Newswire
12.02.21 - PR Newswire
Phio Pharmaceuticals Announces $7.7 Million Registered Direct Offering of Common Stock Priced At-the-Market
Phio Pharmaceuticals Announces $7.7 Million Registered Direct Offering of Common Stock Priced At-​the-Market PR Newswire
25.01.21 - PR Newswire
Phio Pharmaceuticals Announces Closing of $14.0 Million Private Placement Priced At-the-Market
Phio Pharmaceuticals Announces Closing of $14.0 Million Private Placement Priced At-​the-Market PR Newswire
10.11.20 - PR Newswire
Phio Pharmaceuticals Reports Third Quarter 2020 Financial Results and Provides Business Update
Phio Pharmaceuticals Reports Third Quarter 2020 Financial Results and Provides Business Update PR Newswire
21.12.16 - PR Newswire
RXi Pharmaceuticals Announces Closing of $11.5 Million Underwritten Public Offering and Full Exercise of Over-allotment Option
RXi Pharmaceuticals Announces Closing of $11.5 Million Underwritten Public Offering and Full Exercise of Over-​allotment Option PR Newswire
16.12.16 - PR Newswire
RXi Pharmaceuticals Announces Pricing of $10 Million Underwritten Public Offering
RXi Pharmaceuticals Announces Pricing of $10 Million Underwritten Public Offering PR Newswire
13.12.16 - PR Newswire
RXi Pharmaceuticals Provides Year End Update on its Business Development and Clinical Programs
RXi Pharmaceuticals Provides Year End Update on its Business Development and Clinical Programs PR Newswire
10.11.16 - PR Newswire
RXi Pharmaceuticals Reports Third Quarter 2016 Financial Results and Highlights Recent Corporate Developments
RXi Pharmaceuticals Reports Third Quarter 2016 Financial Results and Highlights Recent Corporate Developments PR Newswire
27.10.16 - PR Newswire
RXi Pharmaceuticals to Webcast Third Quarter 2016 Financial Results on Thursday, November 10, 2016
RXi Pharmaceuticals to Webcast Third Quarter 2016 Financial Results on Thursday, November 10, 2016 PR Newswire
12.10.16 - PR Newswire
RXi Pharmaceuticals Plans to Conduct Securities Offering
RXi Pharmaceuticals Plans to Conduct Securities Offering PR Newswire
12.10.16 - PR Newswire
RXi Pharmaceuticals Enters into Exclusive Option Agreement to Acquire MirImmune Inc.
RXi Pharmaceuticals Enters into Exclusive Option Agreement to Acquire MirImmune Inc. Acquisition will broaden RXi's pipeline to include immuno-​oncology with the use of the ...
21.07.16 - PR Newswire
RXi Pharmaceuticals to Present at the 2016 Summer Meeting of the American Academy of Dermatology
RXi Pharmaceuticals to Present at the 2016 Summer Meeting of the American Academy of Dermatology PR Newswire
12.05.16 - PR Newswire
RXi Pharmaceuticals Reports First Quarter 2016 Financial Results and Highlights Recent Corporate Developments
RXi Pharmaceuticals Reports First Quarter 2016 Financial Results and Highlights Recent Corporate Developments PR Newswire
03.05.16 - PR Newswire
RXi Pharmaceuticals and Thera Neuropharma Enter into an Exclusive License Agreement for RXi's Self-Delivering RNAi (sd-rxRNA®) Platform Targeting SOD1 to Develop Therapeutics for Neurodegenerative Dis
RXi Pharmaceuticals and Thera Neuropharma Enter into an Exclusive License Agreement for RXi's Self-​Delivering RNAi (sd-rxRNA®) Platform Targeting SOD1 to Develop ...
28.04.16 - PR Newswire
RXi Pharmaceuticals Announces Advancement of its Ophthalmology Franchise with Successful Topical Delivery of sd-rxRNA to the Cornea in an in vivo Corneal Wound Model
RXi Pharmaceuticals Announces Advancement of its Ophthalmology Franchise with Successful Topical Delivery of sd-rxRNA to the Cornea in an in vivo Corneal Wound Model PR ...
25.04.16 - PR Newswire
RXi Pharmaceuticals to Present at 18th Annual TIDES: Oligonucleotide and Peptides Therapeutics Conference
RXi Pharmaceuticals to Present at 18th Annual TIDES: Oligonucleotide and Peptides Therapeutics Conference PR Newswire
18.04.16 - PR Newswire
RXi Pharmaceuticals to Present at the Association for Research in Vision and Ophthalmology 2016 Annual Meeting
RXi Pharmaceuticals to Present at the Association for Research in Vision and Ophthalmology 2016 Annual Meeting PR Newswire
31.03.16 - PR Newswire
RXi Pharmaceuticals Strengthens Intellectual Property Portfolio for Dermal Indications
RXi Pharmaceuticals Strengthens Intellectual Property Portfolio for Dermal Indications PR Newswire

Newssuche

Videos

newspaper
24.04.24
Technical Trading: AUD/USD mit Mega Chance
AUD/USD Long Typ: Turbo Open End WKN: UM0EHU Hebel: 6,42 Laufzeit: OpenEnd Einstieg: Market ... Mehr »